文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

体外膜氧合治疗COVID-19相关重度急性呼吸窘迫综合征:回顾性队列研究

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study.
PubMed 文献 · Lancet Respir Med · 2020-08-13
一句话结论COVID-19相关重度ARDS接受ECMO者60天生存估计与既往严重ARDS的ECMO研究相似,作者认为在优化治疗后仍难治性呼吸衰竭时可考虑ECMO。

这项在巴黎索邦大学医院网络5个ICU开展的回顾性队列研究,纳入2020年3月8日至5月2日期间接受ECMO的83例COVID-19相关ARDS患者(中位年龄49岁,73%男性),随访至2020年7月10日。ECMO启动前94%已行俯卧位,中位驱动压18 cm H2O、PaO2/FiO2 60 mm Hg。ECMO启动后60天各状态估计概率为:仍在ECMO 6%、在ICU已脱ECMO 18%、存活出ICU 45%、死亡31%;42%发生大出血、5%发生出血性卒中,30例死亡。作者认为其60天生存与近2年严重ARDS的ECMO研究相似,若再次出现COVID-19暴发,对优化治疗后仍难治性呼吸衰竭的患者应考虑ECMO。

要点

  • 83例COVID-19相关ARDS接受ECMO者,ECMO启动后60天存活出ICU的估计概率为45%(95%CI 35-56),死亡状态估计概率31%(95%CI 22-42)。
  • ECMO启动前94%(78例)已行俯卧位,中位驱动压18(IQR 16-21)cm H2O、PaO2/FiO2 60(IQR 54-68)mm Hg,提示为优化通气后仍难治性低氧人群。
  • 出血并发症常见:35例(42%)发生大出血,4例(5%)发生出血性卒中。
  • 60天时仍在ECMO的估计概率仅6%(95%CI 3-14),在ICU已脱ECMO为18%(95%CI 11-28)。
  • 作者认为若再次出现COVID-19暴发,对优化治疗后仍难治性呼吸衰竭的患者应考虑ECMO。

适用人群与场景

  • 巴黎索邦大学医院网络5个ICU内因COVID-19相关ARDS接受ECMO的患者,完整60天随访83例,中位年龄49(IQR 41-56)岁,61例(73%)为男性。
  • 纳入时间为2020年3月8日至5月2日,随访右删失于2020年7月10日。

红旗征与不能漏的情况

  • ECMO期间35例(42%)发生大出血,4例(5%)发生出血性卒中。

研究设计与关键结果

  • 研究类型为回顾性队列研究,在巴黎索邦大学医院网络5个ICU开展,纳入83例接受ECMO的COVID-19相关ARDS患者。
  • ECMO启动前78例(94%)已行俯卧位,中位驱动压18(IQR 16-21)cm H2O,PaO2/FiO2 60(IQR 54-68)mm Hg。
  • ECMO启动后60天各状态估计概率:仍在ECMO 6%(95%CI 3-14)、在ICU已脱ECMO 18%(95%CI 11-28)、存活出ICU 45%(95%CI 35-56)、死亡31%(95%CI 22-42)。
  • 35例(42%)发生大出血,4例(5%)发生出血性卒中,30例死亡。

证据类型、等级与局限

  • 证据类型为回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,若再次出现COVID-19暴发,对优化治疗后仍难治性呼吸衰竭的患者应考虑ECMO。
  • 本队列中ECMO启动前94%已行俯卧位、中位PaO2/FiO2 60 mm Hg,提示所报告结局对应的是优化通气(含俯卧位)后仍难治性低氧的人群。
  • ECMO期间大出血(42%)与出血性卒中(5%)发生率高,床旁管理需按原文报告的比例认识出血风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with COVID-19 who develop severe acute respiratory distress syndrome (ARDS) can have symptoms that rapidly evolve to profound hypoxaemia and death. The efficacy of extracorporeal membrane oxygenation (ECMO) for patients with severe ARDS in the context of COVID-19 is unclear. We aimed to establish the clinical characteristics and outcomes of patients with respiratory failure and COVID-19 treated with ECMO.

METHODS: This retrospective cohort study was done in the Paris-Sorbonne University Hospital Network, comprising five intensive care units (ICUs) and included patients who received ECMO for COVID-19 associated ARDS. Patient demographics and daily pre-ECMO and on-ECMO data and outcomes were collected. Possible outcomes over time were categorised into four different states (states 1-4): on ECMO, in the ICU and weaned off ECMO, alive and out of ICU, or death. Daily probabilities of occupation in each state and of transitions between these states until day 90 post-ECMO onset were estimated with use of a multi-state Cox model stratified for each possible transition. Follow-up was right-censored on July 10, 2020.

FINDINGS: From March 8 to May 2, 2020, 492 patients with COVID-19 were treated in our ICUs. Complete day-60 follow-up was available for 83 patients (median age 49 [IQR 41-56] years and 61 [73%] men) who received ECMO. Pre-ECMO, 78 (94%) patients had been prone-positioned; their median driving pressure was 18 (IQR 16-21) cm H2O and PaO2/FiO2 was 60 (54-68) mm Hg. At 60 days post-ECMO initiation, the estimated probabilities of occupation in each state were 6% (95% CI 3-14) for state 1, 18% (11-28) for state 2, 45% (35-56) for state 3, and 31% (22-42) for state 4. 35 (42%) patients had major bleeding and four (5%) had a haemorrhagic stroke. 30 patients died.

INTERPRETATION: The estimated 60-day survival of ECMO-rescued patients with COVID-19 was similar to that of studies published in the past 2 years on ECMO for severe ARDS. If another COVID-19 outbreak occurs, ECMO should be considered for patients developing refractory respiratory failure despite optimised care.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Schmidt M, Hajage D, Lebreton G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med. 2020. PMID: 32798468. doi:10.1016/S2213-2600(20)30328-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。